Solid Biosciences LLC (SLDB) — Financial Flexibility Index
Solid Biosciences LLC (SLDB) has a Financial Flexibility Index of -0.97x as of March 2026. Free cash flow of $-47.06 Million (operating CF $-47.23 Million minus capex $165.00K) represents -1% of total liabilities ($48.76 Million). Check SLDB capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Solid Biosciences LLC Financial Flexibility Index (2015–2025)
Historical Financial Flexibility Index trend for Solid Biosciences LLC across 11 annual periods. See Solid Biosciences LLC short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Solid Biosciences LLC (2015–2025)
Year-by-year free cash flow to debt coverage for Solid Biosciences LLC. For the full company profile including market capitalisation, see SLDB market cap overview.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.95x | $-155.14 Million | $-156.29 Million | $52.53 Million | ▼ -52.8% |
| 2024 | -1.93x | $-99.36 Million | $-100.01 Million | $51.42 Million | ▲ +19.8% |
| 2023 | -2.41x | $-92.67 Million | $-94.18 Million | $38.46 Million | ▼ -23.3% |
| 2022 | -1.95x | $-94.96 Million | $-97.98 Million | $48.59 Million | ▲ +38.2% |
| 2021 | -3.16x | $-76.48 Million | $-77.76 Million | $24.17 Million | ▼ -122.0% |
| 2020 | -1.43x | $-55.70 Million | $-56.60 Million | $39.08 Million | ▲ +62.2% |
| 2019 | -3.77x | $-88.33 Million | $-92.71 Million | $23.42 Million | ▲ +12.9% |
| 2018 | -4.33x | $-62.42 Million | $-70.20 Million | $14.41 Million | ▼ -1332.5% |
| 2017 | -0.30x | $-40.95 Million | $-43.22 Million | $135.45 Million | ▼ -20.3% |
| 2016 | -0.25x | $-19.73 Million | $-20.12 Million | $78.52 Million | ▼ -398.4% |
| 2015 | -0.05x | $-3.81 Million | $-4.20 Million | $75.62 Million | — |